Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
|
|
Oyster Point Pharma, Inc. (OYST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 0% stake in Oyster Point Pharma, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/13/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 01/13/2023 |
8-K/A
| Resignation/termination of a director |
| 01/13/2023 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 0% stake in OYSTER POINT PHARMA, INC. |
| 01/09/2023 |
SC 13D/A
| New Enterprise Associates 14, L.P. has filed a Schedule 13D for Oyster Point Pharma, Inc. |
| 01/06/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/05/2023 |
SC 13D/A
| InvOpps IV US, L.P. reports a 0% stake in Oyster Point Pharma, Inc. |
| 01/05/2023 |
4
| InvOpps GP IV, L.L.C. (10% Owner) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 917,768 shares
@ $0
Unknown transaction of 1,850,818 shares
@ $0 |
|
| 01/04/2023 |
4
| Versant Venture Capital VI, L.P. (10% Owner) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 2,236,888 shares
@ $0
Unknown transaction of 414,607 shares
@ $0
Unknown transaction of 2,465 shares
@ $0
Unknown transaction of 1,003,658 shares
@ $0 |
|
| 01/04/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Disposed/sold 10,066 shares
@ $0
Disposed/sold 3,573 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/04/2023 |
4
| New Enterprise Associates 14, L.P. (10% Owner) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 5,925,287 shares
@ $0 |
|
| 01/04/2023 |
4
| WEISNER AIMEE S (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Disposed/sold 33,191 shares
@ $0
Disposed/sold 3,573 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/04/2023 |
4
| Tsai Benjamin (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 10,066 shares
@ $0
Disposed/sold 3,573 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/04/2023 |
4
| Santel Donald J (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 5,489 shares
@ $0
Disposed/sold 8,198 shares
@ $0
Disposed/sold 15,170 options to buy
@ $14.25, valued at
$216.2k
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
|
|
| 01/04/2023 |
4
| Ozawa Clare (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Disposed/sold 11,064 shares
@ $0
Disposed/sold 3,573 shares
@ $0
Unknown transaction of 414,607 shares
@ $0
Unknown transaction of 2,465 shares
@ $0
Unknown transaction of 2,236,888 shares
@ $0
Unknown transaction of 1,003,658 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/04/2023 |
4
| Nau Jeffrey (President and CEO) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Paid exercise price by delivering 2,607 shares
@ $11.7, valued at
$30.5k
Unknown transaction of 100,738 shares
@ $0
Disposed/sold 47,975 shares
@ $0
Disposed/sold 1,000 shares
@ $0
Disposed/sold 350,000 rights
@ $0
Disposed/sold 11,031 options to buy
@ $0.2, valued at
$2.2k
Disposed/sold 434,774 options to buy
@ $1.02, valued at
$443.5k
Disposed/sold 387,151 options to buy
@ $5.33, valued at
$2.1M
Disposed/sold 211,533 options to buy
@ $32.65, valued at
$6.9M
Disposed/sold 116,539 options to buy
@ $18.77, valued at
$2.2M
Disposed/sold 210,000 options to buy
@ $16, valued at
$3.4M
|
|
| 01/04/2023 |
4
| Murray Mark Anthony (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Disposed/sold 118,513 shares
@ $0
Disposed/sold 3,573 shares
@ $0
Disposed/sold 15,885 options to buy
@ $0.2, valued at
$3.2k
Disposed/sold 98,604 options to buy
@ $1.02, valued at
$100.6k
Disposed/sold 65,787 options to buy
@ $5.33, valued at
$350.6k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
|
|
| 01/04/2023 |
4
| Lochner Daniel (CFO) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Paid exercise price by delivering 938 shares
@ $11.7, valued at
$11k
Unknown transaction of 56,289 shares
@ $0
Disposed/sold 20,236 shares
@ $0
Disposed/sold 300,000 rights
@ $0
Disposed/sold 161,251 options to buy
@ $11.51, valued at
$1.9M
Disposed/sold 72,648 options to buy
@ $32.65, valued at
$2.4M
Disposed/sold 50,500 options to buy
@ $18.77, valued at
$947.9k
Disposed/sold 45,000 options to buy
@ $13.78, valued at
$620.1k
Disposed/sold 87,900 options to buy
@ $16, valued at
$1.4M
|
|
| 01/04/2023 |
4
| Eliades George Christopher (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Disposed/sold 11,761 shares
@ $0
Disposed/sold 16,863 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/04/2023 |
4
| ATIEH MICHAEL G (Director) has filed a Form 4 on Oyster Point Pharma, Inc.|
Txns:
| Unknown transaction of 18,063 shares
@ $0
Disposed/sold 8,671 shares
@ $0
Disposed/sold 5,359 options to buy
@ $3.63, valued at
$19.5k
Disposed/sold 5,199 options to buy
@ $17.74, valued at
$92.2k
|
|
| 01/03/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/03/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/03/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/03/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/03/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/03/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/03/2023 |
8-K
| Resignation/termination of a director |
| 01/03/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/03/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/23/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 12/22/2022 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 12/20/2022 |
SC 13D/A
| InvOpps IV US, L.P. reports a 10.3% stake in Oyster Point Pharma, Inc. |
| 12/09/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
|
|
|